alue	10	TP53-021	LCE1B-001	Adrenocortical carcinoma [ACC]
w expression	8 6 4 2		LCE1F-001 LCE1D-001 LCE1A-001	TCGA tumors from 79 patients
on valu	70 60 50 40	TP53-021 FLG-001 LCE1C-002 LCE1C-001	LCE1B-001 LCE1F-001 LCE1D-001 LCE1A-001	Bladder Urothelial Carcinoma [BLCA]
≥	30 20 10 0			TCGA tumors from 408 patients
pressior 1		TP53-021 FLG-001 LCE1C-002 LCE1C-001	LCE1B-001 LCE1F-001 LCE1D-001 LCE1A-001	Breast invasive carcinoma [BRCA]
raw	50 0			TCGA tumors from 1095 patients Cervical squamous cell carcinoma and endocervical adenocarcinoma [CESC]
w expression v	80 70 60 50 40 30 20 10	TP53-021 FLG-001 LCE1C-002 LCE1C-001	LCE1B-001 LCE1F-001 LCE1D-001 LCE1A-001	
	25 20	TP53-021 FLG-001 LCE1C-002	LCE1B-001 LCE1F-001 LCE1D-001	TCGA tumors from 304 patients Cholangiocarcinoma [CHOL]
w express	15 10 5 0	LCE1C-001	LCE1A-001	TCGA tumors from 36 patients
ession valu	60 50 40 30 20	TP53-021 FLG-001 LCE1C-002 LCE1C-001	LCE1B-001 LCE1F-001 LCE1D-001 LCE1A-001	Colon adenocarcinoma [COAD]
	10 0			TCGA tumors from 458 patients Lymphoid Neoplasm Diffuse Large B-cell Lymphoma [DLBC]
ıw expression valu	35 30 25 20 15 10 5		LCE1B-001 LCE1F-001 LCE1D-001 LCE1A-001	
	20 00	TP53-021 FLG-001	LCE1B-001	TCGA tumors from 48 patients Esophageal carcinoma [ESCA]
ıw expressi	80 60 40 20 0		LCE1D-001	TCGA tumors from 184 patients
ssion valu	90 80 70 60 50		LCE1B-001 LCE1F-001 LCE1D-001 LCE1A-001	Glioblastoma multiforme [GBM]
raw expr	30 20 10 0			TCGA tumors from 167 patients Head and Neck squamous cell carcinoma [HNSC]
xpression valu	00 00 00 00 00		LCE1B-001 LCE1F-001 LCE1D-001 LCE1A-001	
value	8 7 6	TP53-021	LCE1B-001	TCGA tumors from 521 patients Kidney Chromophobe [KICH]
w expression	5 4 3 2 1	LCE1C-002	LCE1D-001	TCGA tumors from 66 patients
sion valu	20 15		LCE1B-001 LCE1F-001 LCE1D-001 LCE1A-001	Kidney renal clear cell carcinoma [KIRC]
raw expres	5			TCGA tumors from 533 patients
pression valu	20 15 10		LCE1B-001 LCE1F-001 LCE1D-001 LCE1A-001	Kidney renal papillary cell carcinoma [KIRP]
	0	7052.004	10540.004	TCGA tumors from 290 patients LAML
w expression	25 20 15 10 5	TP53-021 FLG-001 LCE1C-002 LCE1C-001	LCE1B-001 LCE1F-001 LCE1D-001 LCE1A-001	
	45 40 35 30	TP53-021 FLG-001 LCE1C-002	LCE1B-001 LCE1F-001 LCE1D-001	TCGA tumors from 179 patients Brain Lower Grade Glioma [LGG]
w expressi	25 20 15 10 5	LCE1C-001	LCE1A-001	TCGA tumors from 516 patients
ssion valu	18 16 14 12 10 8	TP53-021 FLG-001 LCE1C-002 LCE1C-001	LCE1B-001 LCE1F-001 LCE1D-001 LCE1A-001	Liver hepatocellular carcinoma [LIHC]
ê ×	6 4 2 0			TCGA tumors from 371 patients Lung adenocarcinoma [LUAD]
expression valu	35 30 25 20 15 10	TP53-021 FLG-001 LCE1C-002 LCE1C-001	LCE1B-001 LCE1F-001 LCE1D-001 LCE1A-001	
	0	TP53-021	LCE1B-001	TCGA tumors from 517 patients Lung squamous cell carcinoma [LUSC]
w expression	50 00 50	LCE1C-002	LCE1D-001 LCE1A-001	TCGA tumors from 501 patients
ssion valu	45 40 35 30 25	LCE1C-002	LCE1B-001 LCE1F-001 LCE1D-001 LCE1A-001	Mesothelioma [MESO]
raw expre	20 15 10 5 0			TCGA tumors from 87 patients Ovarian serous cystadenocarcinoma [OV]
expression valu	60 40 20 00 80 60 40		LCE1B-001 LCE1F-001 LCE1D-001 LCE1A-001	Ovarian scrous dystadencearcinoma [OV]
	20 0	TP53-021	LCE1B-001	TCGA tumors from 423 patients Pancreatic adenocarcinoma [PAAD]
w expression	12 10 8 6 4 2	LCE1C-002	LCE1F-001 LCE1D-001 LCE1A-001	TCGA tumors from 178 patients
sion value	12 10 8		LCE1B-001 LCE1F-001 LCE1D-001 LCE1A-001	Pheochromocytoma and Paraganglioma [PCPG]
w expre	6 4 2 0			TCGA tumors from 179 patients
ssion valu	25 20 15		LCE1B-001 LCE1F-001 LCE1D-001 LCE1A-001	Prostate adenocarcinoma [PRAD]
	5 0			TCGA tumors from 497 patients Rectum adenocarcinoma [READ]
w expression valu	50 40 30 20 10		LCE1B-001 LCE1F-001 LCE1D-001 LCE1A-001	
	90 80 70 60		LCE1B-001 LCE1F-001 LCE1D-001	TCGA tumors from 167 patients Sarcoma [SARC]
w expressi	60 50 40 30 20 10 0		LCE1D-001	TCGA tumors from 259 patients
ression valu	00 00 00 00	TP53-021 FLG-001 LCE1C-002 LCE1C-001	LCE1B-001 LCE1F-001 LCE1D-001 LCE1A-001	Skin Cutaneous Melanoma [SKCM]
raw expr	00 00 0			TCGA tumors from 469 patients Stomach adenocarcinoma [STAD]
expression valu	90 80 70 60 50 40 30 20	TP53-021 FLG-001 LCE1C-002 LCE1C-001	LCE1B-001 LCE1F-001 LCE1D-001 LCE1A-001	
Ē	10 0	TP53-021	LCE1B-001	TCGA tumors from 419 patients Testicular Germ Cell Tumors [TGCT]
w expression	00 80 60 40 20	FLG-001 LCE1C-002 LCE1C-001	LCE1F-001 LCE1D-001 LCE1A-001	Total types from 450 retirets
sion value	16 14 12 10	TP53-021 FLG-001 LCE1C-002 LCE1C-001	LCE1B-001 LCE1F-001 LCE1D-001 LCE1A-001	TCGA tumors from 150 patients Thyroid carcinoma [THCA]
w express	8 6 4 2	.52.10-001	.JE174-001	TCGA tumors from 505 patients
xpression valu	30 25 20 15	TP53-021 FLG-001 LCE1C-002 LCE1C-001	LCE1B-001 LCE1F-001 LCE1D-001 LCE1A-001	Thymoma [THYM]
	5 0		100	TCGA tumors from 120 patients Uterine Corpus Endometrial Carcinoma [UCEC]
w expression valu	20 00 80 60 40 20	TP53-021 FLG-001 LCE1C-002 LCE1C-001	LCE1B-001 LCE1F-001 LCE1D-001 LCE1A-001	
	25	TP53-021 FLG-001 LCE1C-002	LCE1B-001 LCE1F-001 LCE1D-001	TCGA tumors from 557 patients Uterine Carcinosarcoma [UCS]
w express	15 10 5 0	LCE1C-001	LCE1D-001	TCGA tumors from 57 patients
ssion valu	25 20 15		LCE1B-001 LCE1F-001 LCE1D-001 LCE1A-001	Uveal Melanoma [UVM]
raw exp	5			TCGA tumors from 80 patients